Quent Capital LLC Sells 383 Shares of CVS Health Co. (NYSE:CVS)

Quent Capital LLC reduced its stake in shares of CVS Health Co. (NYSE:CVS) by 18.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,646 shares of the pharmacy operator’s stock after selling 383 shares during the period. Quent Capital LLC’s holdings in CVS Health were worth $112,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. LaFleur & Godfrey LLC increased its stake in shares of CVS Health by 49.9% in the fourth quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator’s stock worth $217,000 after purchasing an additional 1,610 shares in the last quarter. Hantz Financial Services Inc. grew its stake in CVS Health by 20.1% in the 4th quarter. Hantz Financial Services Inc. now owns 2,416 shares of the pharmacy operator’s stock valued at $108,000 after buying an additional 404 shares in the last quarter. Mediolanum International Funds Ltd raised its holdings in CVS Health by 75.2% during the 4th quarter. Mediolanum International Funds Ltd now owns 23,111 shares of the pharmacy operator’s stock valued at $1,013,000 after acquiring an additional 9,917 shares during the period. Heck Capital Advisors LLC purchased a new stake in shares of CVS Health during the fourth quarter worth $185,000. Finally, Waldron Private Wealth LLC boosted its holdings in shares of CVS Health by 4.9% in the fourth quarter. Waldron Private Wealth LLC now owns 7,346 shares of the pharmacy operator’s stock worth $330,000 after acquiring an additional 341 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 1.9%

CVS opened at $63.99 on Friday. The business’s fifty day simple moving average is $65.62 and its 200 day simple moving average is $59.64. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $72.51. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The stock has a market cap of $80.95 billion, a PE ratio of 17.48, a P/E/G ratio of 0.98 and a beta of 0.60.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.31 EPS. As a group, research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.16%. CVS Health’s payout ratio is 63.48%.

Insider Activity

In other news, SVP James David Clark sold 7,513 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. The trade was a 47.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.22% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on CVS shares. Royal Bank of Canada increased their price objective on CVS Health from $74.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 5th. Wolfe Research increased their price target on shares of CVS Health from 67.00 to 70.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Argus set a $77.00 price objective on shares of CVS Health in a research note on Tuesday, February 18th. Leerink Partnrs raised shares of CVS Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 12th. Finally, Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and raised their price target for the company from $55.00 to $75.00 in a report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and a consensus target price of $74.94.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.